期刊文献+

罗格列酮对大鼠急性心肌缺血再灌注损伤的保护作用 被引量:3

Protective effect of rosiglitazone on myocardial ischemia-reperfusion injury in rats
下载PDF
导出
摘要 目的:观察罗格列酮(RSG)对大鼠急性心肌缺血再灌注(I-R)损伤心肌梗死面积、心律失常发生率和心肌病理学改变的影响。方法:结扎大鼠左冠状动脉前降支30 min、再灌注120 min建立大鼠心肌I-R损伤模型,将大鼠随机分为I-R损伤模型组、RSG高剂量(6 mg.kg-1)、低剂量(3 mg.kg-1)组和假手术组,灌胃给药1周后行I-R损伤手术,观察心肌梗死面积、心律失常发生次数和类型、心肌组织学改变和心肌细胞超微结构的变化。结果:与模型组比较,RSG高剂量组心肌梗死面积与左心室面积百分率(IS/LV%,29.3±4.9vs37.6±3.2)以及心肌梗死面积与危险区面积比值(IS/AAR%,76.1±9.6vs93.5±7.4)减少(P<0.05或P<0.01);RSG高量组心律失常评分(2.6±0.4)低于I-R损伤模型组(4.2±0.6)(P<0.05)。RSG组心肌病理组织学和心肌细胞超微结构损伤轻于I-R损伤模型组。结论:RSG可通过减少I-R损伤大鼠心肌梗死面积、减少恶性心律失常的发生及改善病理组织学损伤而起到对大鼠心肌I-R损伤的保护作用。 Objective To observe the effects of rosiglitazone (RSG) on myocardial infarct size (IS), incidence rate of arrhythmias and the pathohistological changes in rat model of acute myocardial ischemia-reperfusion (I-R) injury. Methods The rat myocardial I-R injury model was induced by ligating left anterior descending branch of coronary artery for 30 min and reperfusing for 120 rain. Wistar rats were randomly divided into four groups: I-R group, RSG groups with the doses of 3 and 6 mg· k^- 1 , and sham-operation group. IS, times and types of arrhythmia, pathohistological changes of myocardium tissue and changes of myocardial cell ultrastructure were observed. Results Compared with I-R group, RSG decreased the ratio of IS/LV% (29.3±4.9 vs 37.6±3.2, P〈0.05) and the rate of IS/AAR% (76.1±9.6 vs 93.5±7.4, P〈0.05), reduced the score of arrhythmias (2.6±0.4 vs 46.2 ± 0.6, P〈0.05), the injuries of pathohistology of myocardium and myocardial cell uhrastructure in RSG group were better that those in I-R group. Conclusion RSG has the protective effect on acute myocardial I-R injury in rats, probably by reducing myocardium ischemia area and incidence rate of arrhythmias and ameliorating morphology and uhrastructure of myocardium.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2009年第1期115-118,196,共5页 Journal of Jilin University:Medicine Edition
基金 中央保健局科研基金资助课题(2006)
关键词 罗格列酮 大鼠 WISTAR 缺血再灌注 rosiglitazone rats, Wistar ischemia-reperfusion
  • 相关文献

参考文献11

  • 1Yu DM, Yu P. The consideration about the cardiovascular safety of rosiglitazone [J]. J China Prescribed Drug, 2007, 7 (64): 51-53.
  • 2Nissen SE, Wolski K. Effect of Rosiglitazone on the risk of myocardial Infarction and death from cardiovascular causes [J]. N EnglJ Med, 2007, 356 (24): 2457-2471.
  • 3Khandoudi N, Delerive P, Berrebi-Bertrand I, et al. Rosiglitazone, a peroxisome proliferator-aetivated receptor-γ, inhibits the Jun NH2 terminal kinase/aetivating protein 1 pathway and protects the heart from isehemia/reperfusion injury [J]. Diabetes, 2002, 51: 1507-1514.
  • 4Molavi B, Chen JW, Mehta JL. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK [J]. Am J Physiol Heart Circ Physiol, 2006, 291: H687- H693.
  • 5Johns DG, Ao ZH, Eybye M, et al. Rosiglitazone protects against ischemia/reperfusion-induced leukocyte adhesion in the zucker diabetic fatty rat [J]. JPET, 2005, 315 (3): 1020 -1027.
  • 6Son NH, Park TS, Yamashita H, et al. Cardiomyocyte expression of PPAR7 leads to cardiac dysfunction in mice [J]. J Clini Invest, 2007, 17 (10): 2791-2801.
  • 7Chen, Ma S, Wei LX, al. Cardioprotective and antiarrhythmic effect of U50, 488H in ischemia/reperfusion rat heart [J]. Heart Vessel, 2007, 22: 335- 344.
  • 8Gao F, Yue TL, Shi DW, et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation [J]. Cadiovasc Res, 2002, 53, 414-422.
  • 9Walker MJ, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion [J]. Cardiovasc Res, 1988, 22: 447-455.
  • 10Joosen AM, Bakker AH, Kersten S, et al. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue [J]. BrJ Nutr, 2008, 99 (3): 487- 493.

二级参考文献12

  • 1Faggin E, Puato M, Zardo L,et al. Smooth muscle-specific SM22 protein is expressed in the adventitial cells of balloon-injured rabbit carotid artery [ J ]. Arterioscler Thromb Vasc Biol,1999,19(6) :1393.
  • 2Cai W J, Koltai S, Kocsis E, et al. Remodeling of the adventitia during coronary arteriogenesis[ J]. Am J Physiol Heart Circ Physiol, 2003,284( 1 ) : H31.
  • 3Zhu Y, Kan L, Qi C, et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR[ J]. J Biol Chem ,2000,275 ( 18 ) : 13510.
  • 4Berger J, Mollerand DE. The mechanisms of action of PPARs[ J]. Annu Rev Med,2002 ,53 :409.
  • 5Law RE, Goetze S,Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells[ J]. Circulation, 2000,101 ( 11 ) : 1311.
  • 6Zhu DL, Herembert T, Marche P. Increased proliferation of adventitial fibroblasts from spontaneously hypertensive rat aorta[J]. J Hypertens,1991,9(12) :1161.
  • 7Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia [J]. J Clin Invest, 1996,98(8) :1897.
  • 8Herrmann J, Samee S, Chade A,et al. Differential effect of experimental hypertension and hypercholesterolemia on adventitial remodeling [ J ]. Arterioscler Thromb Vasc Biol, 2005,25 (2) :447.
  • 9Diep QN, El Mabrouk M,Cohn JS,et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin Ⅱ-infused rats: role of peroxisome proliferator-activated receptor-gamma [ J ]. Circulation, 2002,105(19) :2296.
  • 10Creemers EE,Cleutjens JP,Smits JF,et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure [ J ]. Circ Res,2001,89 ( 3 ) : 201.

同被引文献57

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部